Oral propranolol: An effective, safe treatment for infantile hemangiomas

European Journal of Dermatology

Volumn 21, Issue 4, 2011, Pages 558-563

  Zaher, Hesham ^a   Rasheed, Hoda ^a   Hegazy, Rehab A ^a   Hegazy, Ranya A ^b   Abdelhalim, Dalia M ^a   Gawdat, Heba I ^a  

^a Cairo University   (Egypt)

^b Department of pediatrics   (Egypt)

Author keywords

Beta blocker; Cardiovascular assessment; Hemangioma treatment; Infantile hemangioma; Propranolol; Rebound growth

Indexed keywords

PROPRANOLOL;

ARTICLE; CAPILLARY HEMANGIOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GROWTH DISORDER; HUMAN; INFANT; MALE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; TREATMENT DURATION; ULCER;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; FEMALE; HEMANGIOMA; HUMANS; INFANT; MALE; PROPRANOLOL; PROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 80053013008     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2011.1372     Document Type: Article

References (29)

1. Holmes W, Mishra A, Gorst C, Liew S. Propranolol as first-line treatment for rapidly proliferating infantile hemangiomas. J Plast Reconstr Aesthet Surg 2010 (Aug24); Epub ahead of print.
2. Leboulanger N, Fayoux P, Teissier N, Cox A, et al. Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: A preliminary retrospective study of French experience. Int J Pediatr Otorhinolaryngol 2010 (July): 1254-7.
3. Leaute Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-51.
4. Metz BJ, Rubenstein MC, Levy ML, et al. Response of ulcerated perineal hemagniomas of infancy to becoplermin gel, a recombinant human platelet derived growth factor. Arch Dermatol 2004; 140: 867-70.
5. Tan S, Itinteang T, Leadbitter P. Low-dose propranolol for infantile hemangioma. J Plast Reconstr Aesthet Surg 2010; (July7); Epub ahead of print.
6. Bennett ML, Fleischer AB Jr., Chamlin ST, Frieden IJ. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol 2001; 137: 1208-13.
7. Ezekowitz RA, Mulliken JB, Fokman J. Interferon alfa-2a therapy for life threatening hemangiomas of infancy. N Engl J Med 1992; 326: 1456-63.
8. Frieden IJ, Haggstrom AN, Drolet BA, Mancini AJ, et al. Infantile hemangiomas: current knowledge, future directions: proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA. Pediatr Dermatol 2005; 2: 383-406.
9. Williams EF, Stanislaw P, Dupree M, et al. Hemangiomas in infants and children an algorithm for intervention. Arch Facial Plast Surg 2000; 2: 103-11.
10. Manunza F, Syed S, Laguda B, Linward J, et al. Propranolol for complicated infantile hemangiomas: a case series of 30 infants. Br J Dermatol 2010; 162: 466-8.
11. Holmes WJ, Mishra A, Gorst C, Liew SH. Propranolol as first-line treatment for infantile hemangiomas. Plast Reconstr Surg 2010; 125: 420-1.
12. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M Mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 1978; 57: 1072-83.
13. Tajik AJ, Seward JB, Hagler DJ, Mair DD, Lie JT. Two dimensional real-time ultrasonic imaging of the heart and great vessels technique, image orientation, structure identification and validation. Mayo Clin Proc 1978; 53: 271-303.
14. Zimmerman AP, Weigard S, Werner JA, et al. Propranolol therapy for infantile haemangiomas: review of literature. Int J Pediatr Otorhinolaryngol 2010; 74: 338-42.
15. Qin ZP, Liu XJ, Li KL, et al. Treatment of infantile hemangiomas with low dose propranolol: evaluation of short term efficacy and safety. Zhonghua Yi Xue Za Zhi 2009; 89: 3130-4.
16. th international Workshop on Vasular Anomalies. Oral Presentation, 2010 23/04/2010.
17. th international Workshop on Vascular Anomalies. Oral Presentation, 2010 23/04/2010.
18. Michel JL, Patural H. Response to oral propranolol therapy for ulcerated hemangiomas in infancy. Arch Pediatr 2009; 16: 1565-8.
19. North PE, Waner M, Mizeracki A, Nicholas R, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol 2001; 137: 559-70.
20. Itinteang T, Brasch HD, Tan ST, Day DJ. Expression of components of the renin-angiotensin system in proliferating infantile hemangioma may account for propranolol-induced accelerated involution. J Plast Reconstr Aesthet Surg (2010); Ahead of print.
21. Maitland-van der Zee AH, van Wieren-de Wijer DB, de Boer A, et al. Genetic variation in the renin-angiotensin system, use of reninangiotensin system inhibitors and the risk of myocardialinfarction. J Renin Angiotensin Aldosterone Syst. 2010 Dec 16.[Epub ahead of print].
22. Abboud N, Ghazouani L, Kaabi B, Ben-Hadj-Khalifa S, et al. Evaluation of the contribution of renin angiotensin system polymorphisms to the risk of coronary artery disease among Tunisians. Genet Test Mol Biomarkers 2010; 14: 661-6.
23. Sans V, De La Roque ED, Berge J, Grenier N, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009; 124: e423-31.
24. D'Angelo G, Lee H, Weiner RI. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation. J Cell Biochem 1997; 67: 353-66.
25. Laccarino G, Ciccarelli M, Sorriento D, et al. Ischemic neoangiogenesis enhanced by beta2-adrenergic receptor over-expression: a novel role for the endothelial adrenergic system. Circ Res 2005; 97: 1182-9.
26. Storch CH, Hoeger PH. Propranolol for infantile hemangiomas insights into the molecular mechanisms of action. Br J Dermatol 2010; 163: 269-74.
27. Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol 2003 Apr: 48: 477-493.
28. Shashidhar H, Langhans N, Grand RJ. Propanolol in prevention of portal hypertensive hemorrhage in children: a pilot study. J Pediatr Gastroenterol Nutr 1999; 29: 12-7.
29. Love JN, Sikka N. Are 1: 2, tablets dangerous? Beta blocker exposure in toddlers. J Emerg Med 2004; 26: 309-14.